Richard Burr: “We have to address that veteran, as I said in the opening statement, where they are.”

I am concerned Ms. Kotagal lacks impartiality to interpret the law.

I oppose Ms. Kotagal's nomination and urge my colleagues to do the same.

I was surprised and frustrated to hear that these funds were overwhelmingly repurposed from within ASPR, including the stockpile.

Why did FDA agree, and why did the industry agree to longer review times of 128 days on 510(k)'s and provide the agency with so much more money?